Immune Checkpoint Inhibitor-Associated Transverse Myelitis

Yıl 2024, Sayı: Early Access

Furkan Sarıdaş , Farid Hojjati , Emine Rabia Koç , Ömer Faruk Turan

https://doi.org/10.18678/dtfd.1494742

Öz

Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and information about this entity is minimal. ICI-associated transverse myelitis should be considered a rapid and comprehensive differential diagnosis after evaluating infective, metabolic, or other inflammatory-autoimmune pathologies. After diagnosis, early immunomodulation is required through intravenous high-dose methylprednisolone, IVIg, or plasmapheresis. It should be kept in mind that different etiologies may coexist or a superimposed condition may cause each other, and concurrent treatment should not be delayed. Further studies are needed to investigate the neurological manifestations that may develop in association with these therapies further and help establish guidelines for their management. In this case report, a rare case of ICI-associated transverse myelitis in a 62-year-old male patient was presented.

Anahtar Kelimeler

Immune checkpoint inhibitor, adverse event, transverse myelitis

İmmün Kontrol Noktası İnhibitörü ile İlişkili Transvers Miyelit

Öz

İmmün kontrol noktası inhibitörleri (immune checkpoint inhibitors, ICIs) kanser tedavisinde oldukça etkilidir ve giderek daha fazla kullanılmaktadır. Bu nedenle, bağışıklıkla ilişkili advers olaylar şeklinde çeşitli komplikasyonlara ilişkin farkındalık artmaktadır. ICI'ları takiben gelişen transvers miyelit, nadir ancak ciddi bir nörolojik advers olaydır ve bu antite hakkındaki bilgiler çok sınırlıdır. Enfektif, metabolik veya diğer enflamatuar-otoimmün patolojilerin değerlendirilmesinden sonra hızlı ve kapsamlı bir ayırıcı tanı olarak ICI kaynaklı transvers miyelit dikkatle düşünülmelidir. Tanıdan sonra, intravenöz yüksek doz metilprednizolon, IVIg veya plazmaferez şeklinde erken immünomodülasyon gereklidir. Farklı etiyolojilerin bir arada bulunabileceği veya üst üste binen bir durumun birbirine neden olabileceği akılda tutulmalı ve eş zamanlı tedavi geciktirilmemelidir. Bu tedavilere bağlı olarak gelişebilecek nörolojik bulguların daha fazla araştırılması ve bunların yönetimine ilişkin kılavuzların oluşturulmasına yardımcı olmak için daha fazla çalışmaya ihtiyaç vardır. Bu olgu sunumunda, 62 yaşında bir erkek hastada, nadir görülen bir ICI ile ilişkili transvers miyelit vakası sunulmuştur.

Anahtar Kelimeler

İmmun kontrol noktası inhibitörü, advers olay, transvers miyelit

Kaynakça

• Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D, et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-44.
• Narumi Y, Yoshida R, Minami Y, Yamamoto Y, Takeguchi S, Kano K, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018;18(1):95.
• Farina A, Villagrán-García M, Honnorat J. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. Rev Neurol (Paris). 2023;179(5):506-15.
• Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928-33.
• Kim KH, Baek YH, Kang YW, Yoon BA, Moon SY. A case of transverse myelitis following treatment with atezolizumab for advanced hepatocellular carcinoma. Korean J Gastroenterol. 2023;82(1):35-9.
• Chatterton S, Xi S, Jia JX, Krause M, Long GV, Atkinson V, et al. Case series: Immune checkpoint inhibitor-induced transverse myelitis. Front Neurol. 2023;14:1130313.
• Moodie T, Alshaqi O, Alchaki A. Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report. BMC Neurol. 2022;22(1):107.
• Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M, et al. Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e967.
• Bolz S, Ramakrishnan T, Fleischer M, Livingstone E, Stolte B, Thimm A, et al. Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci. 2021;22:100324.
• Esechie A, Fang X, Banerjee P, Rai P, Thottempudi N. A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications. Int J Neurosci. 2023;133(10):1120-3.
• Shibazaki S, Uchiyama S, Tsuda K, Taniuchi N. Copper deficiency caused by excessive alcohol consumption. BMJ Case Rep. 2017;2017:bcr2017220921.
• Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology. 2006;48(2):78-83.
• Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257(6):869-81.
• Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008;80(6):523-31.
• Yan C, Sheehan M, Wilson R. Copper levels in maintenance plasmapheresis (250). Neurology. 2020;94(15 Suppl):250.
• Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102-13.